» Articles » PMID: 19604265

The Glutamic Acid Decarboxylase 65 Immunoglobulin G Subclass Profile Differs Between Adult-onset Type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA) Up to 3 Years After Clinical Onset

Overview
Date 2009 Jul 17
PMID 19604265
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Autoantibodies against glutamic acid decarboxylase 65 (GADA) are found frequently in patients with autoimmune diabetes. Immunoglobulin (Ig)G(1) is the most frequent subclass among the GADA IgG subclasses. IgG(4) is a more common subclass in latent autoimmune diabetes in adults (LADA) at clinical onset compared to type 1 diabetes. The aim of this work was to study the different GADA-IgG subclass profiles during a 3-year follow-up in these groups of autoimmune diabetes. Adult-onset subjects, classified as either type 1 (n = 40) or LADA (n = 43), were included in the study. New samples were collected every year from these patients. In addition to conventional GADA analyses, GADA-IgG subclasses were also analysed with a radioimmunoprecipitation assay using biotin-conjugated antibodies (directed against human IgG subclasses and IgM) and streptavidin Sepharose. During 3 years' follow-up, all the IgG subclass levels decreased in type 1 diabetes - IgG(1): P < 0.001; IgG(2): P < 0.001; IgG(3): P < 0.001; IgG(4): P < 0.05 (Friedman's' test) - while levels remained stable for all four subclasses in LADA. GADA IgM, however, decreased in both groups (P < 0.001). Patients with LADA have higher GADA IgG(3) and IgG(4) at clinical onset and seem to maintain the levels and profile of their IgG subclasses up to 3 years after clinical onset, while all the GADA IgG subclass levels decrease in type 1 diabetic patients. This indicates a persistent different immune response in LADA compared to type 1 diabetes and further indicates the difference in pathogenesis.

Citing Articles

Variation of C peptide decay rate in diabetic patients with positive glutamic acid decarboxylase antibody: better discrimination with initial fasting C peptide.

Li X, Huang G, Lin J, Yang L, Zhou Z BMC Endocr Disord. 2013; 13:10.

PMID: 23452723 PMC: 3598544. DOI: 10.1186/1472-6823-13-10.

References
1.
Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L . Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care. 2003; 26(2):452-7. DOI: 10.2337/diacare.26.2.452. View

2.
Torn C, Landin-Olsson M, Ostman J, SCHERSTEN B, Arnqvist H, Blohme G . Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev. 2000; 16(6):442-47. DOI: 10.1002/1520-7560(2000)9999:9999<::aid-dmrr152>3.0.co;2-t. View

3.
Gale E . Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia. 2005; 48(11):2195-9. DOI: 10.1007/s00125-005-1954-5. View

4.
Falorni A, Ortqvist E, Persson B, Lernmark A . Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods. 1995; 186(1):89-99. DOI: 10.1016/0022-1759(95)00139-2. View

5.
Loffreda S, Yang S, Lin H, Karp C, Brengman M, Wang D . Leptin regulates proinflammatory immune responses. FASEB J. 1998; 12(1):57-65. View